Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
Mayo Clinic in Florida, Jacksonville, Florida, United States
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Local Institution - 145, Los Angeles, California, United States
Local Institution - 122, Los Angeles, California, United States
Local Institution - 131, Atlanta, Georgia, United States
ISSSTE, Ciudad de Mexico, Mexico
Moi University School of Medicine, Eldoret, Kenya
UNC Project Malawi, Lilongwe, Malawi
Uganda Cancer Institute, Kampala, Uganda
UCSD Moores Cancer Center, La Jolla, California, United States
Holden Comprehensive Cancer Center / University of Iowa, Iowa City, Iowa, United States
Weill Cornell Medicine, New York, New York, United States
Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Norfolk and Norwich Univ Hosp /ID# 202240, Norwich, Norfolk, United Kingdom
Hospital Universitario Vall d'Hebron /ID# 200967, Barcelona, Spain
Washington University-School of Medicine /ID# 201287, Saint Louis, Missouri, United States
University of Maryland Medical Center /ID# 217422, Baltimore, Maryland, United States
UPMC Hillman Cancer Ctr /ID# 200063, Pittsburgh, Pennsylvania, United States
Cleveland Clinic Main Campus /ID# 202247, Cleveland, Ohio, United States
Onkozentrum Hirslanden Zürich, Zurich, Switzerland
OnkoZentrum Zürich AG - Klinik im Park, Zürich, Switzerland
Kantonspital Aarau, Aarau, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.